Study reassures patients about semaglutide safety

Taking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania published this week in JAMA Internal Medicine.

2024 VC forecast: Clinical-stage CDMOs likely to have uptick in demand but specialization critical

Clinical-stage CDMOs should expect a rise in demand in 2024 as funding for early-stage biopharma stabilizes and biotechs may shed their in-house manufacturing to save

December 1, 2023

Home Induction is Effective and Safe for Moms and Babies

NATIONAL HARBOR, Md. — More than two-thirds of nulliparous women achieved vaginal delivery after outpatient induction of labor (IOL), the HOME INDUCTION randomized noninferiority trial

February 16, 2024

Jazz Pharma’s Enrylaze wins European approval for AML and LBL – Pharmaceutical Technology

A 3D illustration showing abundant lymphoblasts in blood. Enrylaze, sold as RylaZe in the US and Canada, was approved by the US Food and Drug

September 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.